Catalyst Event
CSPC Pharmaceutical Group Ltd (1093) · Earnings Release
From Akros SCHK HK-US Biotech Index (ASHUBIO)
3/25/2026, 12:00:00 AM
Full-year 2025 results announcement on March 25, 2026, reporting revenue of RMB 26.01 billion (-10.4% YoY) and net profit of RMB 3.88 billion (-10.3% YoY); high importance reflects the expected significant negative market reaction to declining profitability scheduled.
Korean Translation
2026년 3월 25일 2025년 연간 실적 발표에서 매출 260.1억 위안(10.4% 감소) 및 순이익 38.8억 위안(10.3% 감소)이 보고될 예정이며, 실적 부진에 따른 큰 폭의 주가 하락이 예상됨.
Related Recent Events
CSPC Pharmaceutical Group Ltd (1093) · Other
Final dividend of HKD 0.15 per share for FY2025 (total HKD 0.29, +11.5% YoY) with ex-dividend date June 24, 2026; low importance as dividend increases typically result in minor positive price adjustments scheduled.
6/24/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
High importance is estimated due to the potential for significant price volatility for Pfizer's Q1 2026 earnings release and conference call, scheduled.
5/5/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release and conference call scheduled; typically results in moderate price movement.
4/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q1 2026 earnings release and conference call scheduled.
4/30/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Q1 2026 earnings release and conference call for 2026-04-30, estimated to have a low impact of ~1-2% based on historical trends, scheduled.
4/30/2026, 12:00:00 AM
Regeneron Pharmaceuticals Inc (REGN) · Earnings Release
Regeneron is scheduled to report its first quarter 2026 financial and operating results on 2026-04-29. Importance is Medium as earnings typically drive significant price movement, scheduled.
4/29/2026, 12:00:00 AM